Top 10 Questions Community Oncologists Ask About CELMoDs For MM

Activity Description

Despite significant therapeutic advances, MM remains a complex and ultimately relapsing malignancy characterized by cycles of remission and recurrence, with diminishing responses over time. Patients with relapsed/refractory MM (RRMM) face an especially high treatment burden, as clinicians must navigate an increasingly crowded and rapidly evolving therapeutic landscape that includes immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies. Many of the newer options, while effective, are associated with logistical challenges, safety considerations, and access barriers that can complicate their use in community settings. As a result, substantial unmet needs persist, underscoring the importance of continued innovation and education.

Emerging therapies such as cereblon E3 ligase modulators (CELMoDs) represent a promising next generation of immunomodulatory agents with the potential to reshape the MM treatment paradigm. With encouraging early clinical data and ongoing late-stage trials, CELMoDs may offer effective, more accessible treatment options with tolerable safety profiles. However, because these agents are not yet FDA-approved and data are rapidly evolving, many community oncologists remain uncertain about their mechanisms, clinical utility, and future placement within treatment algorithms.

Led by MM expert Dr. Joseph Mikhael, this activity is designed to equip clinicians with the knowledge and confidence needed to stay current with emerging data and anticipate how CELMoDs may be integrated into future MM management strategies.

Target Audience

This educational activity is intended for medical oncologists, hematologists, hematology/oncology (hem/onc) fellows, and advanced practice providers (APPs) involved in the treatment of hematologic malignancies, especially multiple myeloma (MM).

Educational Objectives 

After completing this activity, the participant should be better able to:

• Discuss the pathophysiologic rationale that led to the development of novel immunomodulatory agents for the treatment of MM
• Describe the emerging efficacy and safety data associated with CELMoD therapy in development for the treatment of MM
• Explain how novel CELMoD therapies would fit into future treatment algorithms for MM

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal. 

Integritas Contact Information

For more information about this activity, please contact Integritas Communications at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Joseph Mikhael, MD, MEd, FRCPC, FACP

• Consulting Fees: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini, Sanofi

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.